Alexandre Harari

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

Transepithelial transport of HIV-1 by M cells is receptor-mediated.

Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.

Antiviral memory T cell responses: correlation with protective immunity and implication for vaccine development.

Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.

Cytomegalovirus (CMV)-specific cellular immune responses.

Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load.

HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

Understanding what makes a good versus a bad vaccine.

Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases.

Functional signatures of protective antiviral T-cell immunity in human virus infections.

Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.

Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization.

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.

Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype.

HIV-1-specific immune response.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.

Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.

Role of HIV-1-specific CD4 T cells.

Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.

Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.

Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.

Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure.

DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.

Functional avidity: a measure to predict the efficacy of effector T cells?

Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.

CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.

Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis.

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.

Personalized approaches to active immunotherapy in cancer.

Neoantigen-based cancer immunotherapy.

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Sensitive and frequent identification of high avidity neo-epitope specific CD8 T cells in immunotherapy-naive ovarian cancer.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.

Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.

High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 T cells.

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.